Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Zantac TM
Active ingredients: ranitidine
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
1. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Store in a Dry Place
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White, film-coated biconvex tablets, engraved on one side with "RAN 150" and plain on the other


Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 2 tablets (starter pack) pack
- 6 tablets pack
- 60 tablets pack
We are unable to tell you if you need a prescription for these medicines. You can ask your pharmacist. This medicine is Not Scheduled.
- 90 tablets (E) pack
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesphagitis. The intravenous injection is indicated where oral treatment is inappropriate.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Store in a Dry Place
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White, film-coated biconvex tablets, engraved on one side with "RAN 300" and plain on the other


Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage: maintenance treatment to reduce the risk of relapse in duodenal ulcer: maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer: treatment of gastrinoma (Zollinger-Ellison syndrome): short-term treatment of severe reflux oesophagitis: treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate. NEW INDICATIONS AS AT 2 NOVEMBER 1993: 1. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate. INDICATIONS AS AT 31 OCTOBER 1995: 1. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Shelf lifetime is 2 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear pale yellow liquid in the above container.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
INDICATIONS AS AT 2 NOVEMBER 1993: 1. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids.INDICATIONS AS AT 11 FEBRUARY 2005: 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate.
How to take it
The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
- Store below 25 degrees Celsius
- Shelf lifetime is 2 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear colourless to pale yellow liquid, practically free from visible particles.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
Short term treatment of proven duodenal and gastric ulcer. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. Treatment of gastrinoma (Zollinger-Ellison syndrome). Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. Treatment of scleroderma oesophagitis. NEW INDICATIONS AS AT 2 NOVEMBER 1993: 1. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short- term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and siomple drug therapies such as antacids. 6. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate. INDICATIONS AS AT 31 OCTOBER 1995: Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Protect from Moisture
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White to pale yellow, round, bevelled tablets marked "GS LHK" on one side and flat on the other.



Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
Short term treatment of proven duodenal and gastric ulcer. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. Treatment of gastrinoma (Zollinger-Ellison syndrome). Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. Treatment of scleroderma oesophagitis. INDICATIONS AS AT 2 NOVEMBER 1993: 1. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate. INDICATIONS AS AT 31 OCTOBER 1995: 1. Short-term treatment of provenduodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ucler. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Protect from Moisture
- Shelf lifetime is 18 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White to pale yellow, round, bevelled tablets marked "GS LHK" on one side and flat on the other.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
1. Short-term treatment of provenduodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ucler. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Protect from Moisture
- Shelf lifetime is 18 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White to pale yellow, round, bevelled tablets marked "GS MJG" on one side and flat on the other
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
Short term treatment of proven duodenal and gastric ulcer. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. Treatment of gastrinoma (Zollinger-Ellison syndrome). Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. Treatment of scleroderma oesophagitis. NEW INDICATIONS AS AT 2 NOVEMBER 1993: 1. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short- term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and siomple drug therapies such as antacids. 6. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate. INDICATIONS AS AT 31 OCTOBER 1995: Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Protect from Moisture
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White to pale yellow, round, bevelled tablets marked "GS LHK" on one side and flat on the other.



Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
1. Short-term treatment of provenduodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ucler. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Protect from Moisture
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White to pale yellow, round, bevelled tablets marked "GS MJG" on one side and flat on the other.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
Short term treatment of proven duodenal and gastric ulcer. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. Treatment of gastrinoma (Zollinger-Ellison syndrome). Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. Treatment of scleroderma oesophagitis. NEW INDICATIONS AS AT 2 NOVEMBER 1993: 1. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short- term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and siomple drug therapies such as antacids. 6. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate. INDICATIONS AS AT 31 OCTOBER 1995: Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Protect from Moisture
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White to pale yellow, round, bevelled tablets marked "GS LHK" on one side and flat on the other.



Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
1. Short-term treatment of provenduodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ucler. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Protect from Moisture
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White to pale yellow, round, bevelled tablets marked "GS MJG" on one side and flat on the other.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
1. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Store in a Dry Place
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
A pink, five-sided biconvex tablet, engraved with 'Z' on one face and '75' on the other.
Do I need a prescription?
The packs below are available from a pharmacy without prescription. It is Schedule 3 : Pharmacist Only Medicine.
- 12 tablets pack
- 56 tablets pack
- 6 tablets pack
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 120 tablets pack
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
1. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Store in a Dry Place
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
A pink, five-sided biconvex tablet, engraved with 'Z' on one face and '75' on the other.
Do I need a prescription?
The packs below are available from a pharmacy without prescription. It is Schedule 3 : Pharmacist Only Medicine.
- 12 tablets pack
- 56 tablets pack
- 6 tablets pack
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 120 tablets pack
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
1. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Store in a Dry Place
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
A pink, five-sided biconvex tablet, engraved with 'Z' on one face and '75' on the other.
Do I need a prescription?
The packs below are available from a pharmacy without prescription. It is Schedule 3 : Pharmacist Only Medicine.
- 12 tablets pack
- 56 tablets pack
- 6 tablets pack
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 120 tablets pack
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
1. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesophagitis. The intravenous injection is indicated where oral treatment is inappropriate
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Store in a Dry Place
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
A pink, five-sided biconvex tablet, engraved with 'Z' on one face and '75' on the other.
Do I need a prescription?
The packs below are available from a pharmacy without prescription. It is Schedule 3 : Pharmacist Only Medicine.
- 12 tablets pack
- 56 tablets pack
- 6 tablets pack
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
- 120 tablets pack
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
1. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesphagitis. The intravenous injection is indicated where oral treatment is inappropriate
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Store in a Dry Place
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
A white, capsule shaped film-coated tablet with a breakline.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
The Therapeutic Goods Administration (TGA) has a recall notice on this product.
The Therapeutic Goods Administration (TGA) has issued an alert on ranitidine. For more information and the latest updates, see TGA's alert on ranitidine.
What it is used for
1. Short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. Maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. Maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. Treatment of gastrinoma (Zollinger-Ellison syndrome). 5. Short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. Maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. Treatment of scleroderma oesphagitis. The intravenous injection is indicated where oral treatment is inappropriate
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Store in a Dry Place
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
A white, capsule shaped film-coated tablet with a breakline.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.
Pregnant or planning a pregnancy?
For the active ingredient ranitidine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
Heartburn treatments - MyDr.com.au
Treatment for heartburn will depend on how often your heartburn occurs and how much it impacts on your life. Treatments include antacids, medicines or surgery, as well as self-help measures.
Read more on myDr website

Heartburn - MyDr.com.au
Heartburn is a common form of indigestion caused by gastro-oesophageal reflux - reflux of stomach contents into the oesophagus (gullet).
Read more on myDr website

Hiatus hernia: symptoms, causes, self-care and treatment
Most hiatus hernias don't cause any symptoms. When symptoms do occur, the most common are heartburn and regurgitation of stomach acid into the mouth.
Read more on myDr website

Impotence causes - MyDr.com.au
Find out the physical and psychological causes of impotence, also called erectile dysfunction or ED.
Read more on myDr website

Top results